Skip to content

EPS (Diluted) at other companies

ALN
Alnylam PharmaceuticalsALNY
$1.51+1,179%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$0.19+61.2%
Regenxbio logo
RegenxbioRGNX
-$1.72-1,533%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$0.10
Opko Health logo
Opko HealthOPK
-$0.07+30.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$0.44-30.2%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's EPS (diluted)?
Tectonic Therapeutics (TECX) reported EPS (diluted) of -$1.34 in Q1 2026.
How has Tectonic Therapeutics's EPS (diluted) changed year-over-year?
Tectonic Therapeutics's EPS (diluted) decreased by 44.1% year-over-year, from -$0.93 to -$1.34.
What is the long-term trend for Tectonic Therapeutics's EPS (diluted)?
Over 3 years (2021 to 2025), Tectonic Therapeutics's EPS (diluted) has grown at a 13.2% compound annual growth rate (CAGR), from -$2.79 to -$4.05.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.